Alx Oncology Holdings Total Liabilities
Alx Oncology Holdings total liabilities. Based on the latest financial reports, Alx Oncology Holdings (ALXO) has total liabilities worth $24.63 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Alx Oncology Holdings liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Alx Oncology Holdings (2018–2025)
Total liabilities of Alx Oncology Holdings from 2018 to 2025. This chart illustrates how Alx Oncology Holdings 's total liabilities have evolved over time, based on quarterly financial data. Explore ALXO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Alx Oncology Holdings Competitors by Total Liabilities
The table below lists competitors of Alx Oncology Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Falcon Oil & Gas Ltd
F:FAC
|
Germany | €18.06 Million |
|
Thanulux Public Company Limited
BK:TNL
|
Thailand | ฿4.77 Billion |
|
Spandana Sphoorty Financial Limited
NSE:SPANDANA
|
India | Rs-21.30 Billion |
|
Asian Sea Corporation Public Company Limited
BK:ASIAN
|
Thailand | ฿1.24 Billion |
|
King Core Electronics Inc
TW:6155
|
Taiwan | NT$649.91 Million |
|
Nova Minerals Ltd
AU:NVA
|
Australia | AU$30.55 Million |
|
Rockfields Property Indonesia Pt
JK:ROCK
|
Indonesia | Rp114.49 Billion |
|
Sierra Metals Inc.
TO:SMT
|
Canada | CA$269.76 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Alx Oncology Holdings 's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Alx Oncology Holdings total assets.
Liquidity & Leverage Metrics
Alx Oncology Holdings Total Liabilities Ratios Explained
Alx Oncology Holdings total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alx Oncology Holdings 's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alx Oncology Holdings (2018–2025)
The table below shows the annual total liabilities of Alx Oncology Holdings from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $33.06 Million | -3.20% |
| 2024-12-31 | $34.16 Million | -35.36% |
| 2023-12-31 | $52.84 Million | +22.81% |
| 2022-12-31 | $43.02 Million | +151.11% |
| 2021-12-31 | $17.13 Million | +175.95% |
| 2020-12-31 | $6.21 Million | -43.31% |
| 2019-12-31 | $10.95 Million | +445.15% |
| 2018-12-31 | $2.01 Million | -- |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more